source
- Inhibrx reports promising mid-stage data for OX40 agonist and plans vaccine combos early next yearInhibrx Biosciences announced that its OX40 agonist showed encouraging activity in a mid-stage trial involving immunogenic cancers. The data suggest the agent may also enhance responses when paire…
- Funding shortfall threatens progress of new Ebola vaccine candidatesA rapidly expanding Ebola outbreak in Africa has spurred multiple groups to accelerate vaccine development. The effort is being coordinated by a key global health organization, but the group is fa…